On August 26, AMETEK (NYSE:AME) closed one of the largest deals in its history, an all-cash purchase of Indicor Instrumentation for $5.0 billion. The timing is notable. Three weeks earlier, on August 4, AMETEK had just posted record quarterly sales and raised its full-year guidance. Put the two together, and a pattern emerges: a company using a stretch of exceptional organic performance to fund an even bigger swing at growth.
Orders Are Piling Up Fast
AMETEK’s second quarter told the story before the acquisition even closed. Sales hit a record $2.04 billion, up 15% from the same period in 2025, and adjusted earnings climbed 17% to $2.09 per diluted share. Operating margins expanded to 26.6%, a 60 basis point improvement, while operating cash flow jumped 35% to $483.7 million. Free cash flow conversion ran at 111% of net income, meaning AMETEK generated more cash than the accounting profit alone would suggest. Orders grew 28% in the quarter, the second straight quarter of what the company called exceptional demand, with the Electronic Instruments Group seeing particular strength in semiconductor and commercial aerospace markets and the Electromechanical Group benefiting from medtech, defense and automation orders.
The Indicor Instrumentation purchase builds directly on that momentum. The acquired businesses make mission-critical instrumentation for industrial and scientific customers, in end markets that align closely with AMETEK’s existing portfolio, and generate recurring income from consumables, service work and aftermarket support long after the initial sale. Indicor Instrumentation is expected to add roughly $350 million to 2026 sales and be modestly accretive to adjusted earnings this year, and the businesses are being folded into AMETEK’s existing Electronic Instruments and Electromechanical groups rather than run as a separate unit.
The Price Of Growing Fast
Not every number in the release flatters the story equally. AMETEK’s GAAP earnings of $1.77 per diluted share ran well below the adjusted $2.09 figure, a 32-cent gap made up of non-cash charges tied to its acquisition history, plus one-time deal and integration expenses, a reminder that the growth machine carries real ongoing costs that adjusted figures tend to smooth over. The Indicor Instrumentation deal adds another $5.0 billion of cash spent in a single transaction, and AMETEK’s own executives frame the payoff as coming from successfully integrating the acquired businesses into its operating model, which is another way of saying the value still depends on execution rather than being locked in at closing.
What The Smart Money Sees
Hedge fund ownership of AMETEK slipped from 70 funds to 69 in the most recent quarter, a marginal step back rather than a retreat. Short interest sits at just 1.27% of the float, which points to almost no organized bets against the stock. Yet AMETEK trades at a forward price-to-earnings ratio of 26.88 as of September 18, a multiple that already prices in continued double-digit earnings growth. That combination, light skepticism paired with a rich valuation, leaves little room for a stumble to go unpunished.
A Premium With Proof Behind It
AMETEK enters the second half of 2026 with raised guidance, a freshly closed $5.0 billion acquisition and a third-quarter outlook calling for adjusted earnings of $2.08 to $2.10 per share. For the growth to justify the multiple, the Indicor Instrumentation integration needs to go as smoothly as management expects, and the recurring revenue it brings needs to hold up as promised. For the skeptics, the widening gap between GAAP and adjusted earnings is the number worth watching next. Either way, the second half of 2026 will show whether this latest deal was well timed or simply well funded.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
